Brzozow

• A Phase 2 Study of JNJ-79635322 in Participants with RRMM Recruiting
  2025-521976-80-00 4 2026-05-28 Relapsed or Refractory Multiple Myeloma (RRMM)
• A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB 3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Pre … Recruiting
  2025-524366-21-00 5 2026-04-29 treatment-naive Chronic Lymphocytic Leukemia
• A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab. Recruiting
  2025-521639-34-00 3 2026-04-20 • Non-small cell lung cancer (Stage III, unresectable) • Small cell lu
• The SEAMARK Study: Phase 2 Study of First-line Encorafenib and Cetuximab Plus Pembrolizumab in Participants With BRAF V600E-mutant,MSIH/dMMR … Recruiting
  2024-512119-34-00 4 2022-06-20 MSI-H/dMMR metastatic colorectal cancer
• An unblinded, multi-center study evaluating long-term treatment with Zanubrutinib (BGB-3111) regimens in patients with blood cancer in the l … Recruiting
  2024-511267-28-00 5 2021-02-17 B-cell malignancies
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-02) Recruiting
  2025-522873-12-00 5 2026-02-24 ER+, HER2- Advanced Breast Cancer
• A Study in TKI-naive Patients With Advanced ALK-Positive NSCLC ( ALKAZAR ) Recruiting
  2024-517553-26-00 5 2025-11-12 Advanced ALK-positive non-small cell lung cancer (NSCLC)
• Evaluation of efficacy and safety of GSK5764227 (alone and in combination) in participants with previously treated advanced unresectable or … Recruiting
  2025-520672-26-00 9 2025-09-16 Gastrointestinal Neoplasms
• A Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituxima … Recruiting
  2024-518893-15-00 5 2025-07-29 Chronic lymphotic leukemia and Small Lymphocytic lymphoma
• A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) i … Recruiting
  2024-516633-12-00 5 2025-06-30 Locally advanced/ metastatic gastroesophageal junction and gastric can
• Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Recruiting
  2024-513853-66-00 5 2025-02-04 KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colo
• Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Canc … Recruiting
  2024-513852-13-00 5 2025-01-20 KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Col
• MAGIC AML - Multiarm, Multicenter, RAndomized, Molecularly-GuIded Controlled Trial of Personalized Treatment Strategy - of Acute Myeloid Leu … Recruiting
  2023-503394-37-00 5 2024-10-23 Acute Myeloid Leucaemia
• Multi-cohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia TAILOR Recruiting
  2023-504044-34-00 4 2024-04-17 Untreated Chronic Lymphocytic Leukemia
• STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C … Recruiting
  2023-505871-63-00 5 2024-04-08 ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination … Recruiting
  2023-503442-30-00 5 2022-10-14 Multiple Myeloma
• A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer Ended recruitment
  2024-519773-19-00 5 2025-07-31 Gastroesophageal Junction Adenocarcinoma
• A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal- … Ended recruitment
  2022-502446-27-00 5 2024-02-26 Relapsed or Refractory Myeloma
• A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB … Ended recruitment
  2023-506139-13-00 5 2024-01-04 Treatment naïve patients with MF
• A Study to Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination with Polatuzumab Vedotin Plus Rituximab, Cyclophospha … Ended recruitment
  2023-504028-24-00 5 2023-09-22 Large B-Cell Lymphoma
• A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Met … Ended recruitment
  2023-505816-39-00 4 2023-04-04 Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carci
• (Peak) A Clinical Study of CGT9486+Sunitinib vs Sunitinib in Patients with Gastrointestinal Stromal Tumors Ended recruitment
  2022-500637-80-00 5 2023-03-28 gastrointestinal stromal tumor
• A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combin … Ended recruitment
  2023-503467-41-00 5 2022-10-12 Relapsed or Refractory Multiple Myeloma
• A Phase 3 Study of Rusfertide (PTG-300) in Patients with Polycythemia Vera Ended recruitment
  2023-509750-58-00 5 2022-09-21 Polycythemia Vera

Showing 1–24 of 38 trials